Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | MEDI7247 |
Synonyms | |
Therapy Description |
MEDI7247 is an antibody-drug conjugate consisting of a monoclonal antibody to SLC1A5 (ASCT2) and and the cytotoxic agent, pyrrolobenzodiazepine (AACR; Cancer Res 2018;78(13 Suppl):Abstract nr LB-295). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MEDI7247 | MEDI-7247|MEDI 7247 | MEDI7247 is an antibody-drug conjugate consisting of a monoclonal antibody to SLC1A5 (ASCT2) and and the cytotoxic agent, pyrrolobenzodiazepine (AACR; Cancer Res 2018;78(13 Suppl):Abstract nr LB-295). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03106428 | Phase I | MEDI7247 | A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies | Completed | USA | FRA | 1 |
NCT03811652 | Phase I | MEDI7247 | A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors | Completed | USA | CAN | 0 |